Corcept Therapeutics Incorporated - Common Stock (CORT)
83.87
+1.14 (1.38%)
NASDAQ · Last Trade: Sep 28th, 12:27 AM EDT
Detailed Quote
Previous Close
82.73
Open
83.81
Bid
83.87
Ask
90.00
Day's Range
82.78 - 84.89
52 Week Range
42.01 - 117.33
Volume
484,078
Market Cap
9.72B
PE Ratio (TTM)
74.88
EPS (TTM)
1.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
890,031
Chart
About Corcept Therapeutics Incorporated - Common Stock (CORT)
Corcept Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for patients with severe metabolic and psychiatric disorders. The company primarily specializes in the modulation of glucocorticoid signaling, a pathway that plays a key role in various diseases, particularly those characterized by chronic stress and inflammation. Corcept's lead product is designed to help patients suffering from conditions such as Cushing's syndrome, and the company is also engaged in research aimed at expanding its therapeutic applications to broader health issues. Through its dedication to advancing scientific understanding and developing effective therapies, Corcept aims to improve the quality of life for patients battling these challenging health conditions. Read More
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 5.4% in the afternoon session after the company announced it would present new data from its pivotal Phase 3 ROSELLA trial and that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application for relacorilant, a treatment for platinum-resistant ovarian cancer.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The data, which will be presented in a late-breaking oral presentation on Sunday, October 19, 2025, focuses on trial participants who were previously treated with a PARP inhibitor, a patient population with particularly poor prognosis.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Corcept (NASDAQ:CORT) and the best and worst performers in the branded pharmaceuticals industry.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept’s New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. The FDA has assigned a PDUFA date of July 11, 2026 for the application.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Discover Corcept Therapeutics (CORT), an affordable growth stock with strong revenue growth, high profitability, and a compelling valuation within the pharmaceuticals sector.
Corcept Therapeutics (CORT) shows strong growth, profitability, and technical momentum, making it a top pick for investors seeking high-potential stocks.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 2.6% below analysts’ estimates. Its non-GAAP profit of $0.29 per share was 54.7% above analysts’ consensus estimates.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 2.7% below analysts’ estimates. Its GAAP profit of $0.29 per share was 28.4% above analysts’ consensus estimates.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025.
CORCEPT THERAPEUTICS (CORT) offers strong growth potential with fair valuations, solid profitability, and a healthy balance sheet, making it an attractive pick for Affordable Growth investors.
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong revenue growth, high profitability, and a promising technical setup, making it a noteworthy candidate for growth investors.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer.
